Page 20 - Jon Burrows News Today : Breaking News, Live Updates & Top Stories | Vimarsana

About Oxford BioDynamics Plc Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. In March 2021, the Company launched its first commercial prognostic...

    Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, announces that it has today granted a total of 1,632,798 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 462,798 options to Chief Executive Officer, Dr Jon Burrows, 480,000 options to Chief Financial Officer, Paul Stockdale and 150,000 options to Chief Operating Officer, Thomas Guiel, who is a person discharging manageria...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

at Oxford Business Park, supporting expanded strategy Oxford, UK - 9 April 2021 -  Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, has signed a lease agreement for new laboratory and office space at Oxford Business Park , to significantly expand its UK facilities. The 24,000 sq ft premises will house the Company's growing UK infrastructure, as it continues the execution of its expanded strategic focus , announ...

TRADING UPDATES: Novacyt expands VersaLab with rapid Covid tests Wed, 17th Mar 2021 14:44 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Novacyt SA - Anglo-French biotechnology group focused on clinical diagnostics - Announces the expansion of its VersaLab service with the launch of mobile processing laboratories to provide rapid turnaround PCR testing for Covid-19 on-site. "Throughout the Covid-19 pandemic, Novacyt has focused on innovation to ensure we adapt in line with a rapidly evolvin...